Skip to content
value.today

CHD Bioscience, Inc.

Total raised
$14 M
6 rounds on record
Latest round
$1 M
Jun 2025
First round on record
Feb 2014
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of CHD Bioscience, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2025$1 MNo. 6Under $2 million

CHD Bioscience, Inc.: Raise no. 6, Jun 2025

Investors in this round

1 investor had bought by the notice of Jul 10, 2025: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $3 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$150,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael Voss · Executive Officer, Director
  • Steve Coder · Executive Officer, Director
  • Alan Ruud · Director
  • Alan Smith, Ph.D. · Director
  • Christopher Rudd · Director
  • Michael Litwack · Director
  • Theodore Ziemann · Director
  • William Nelson, MD, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steve Coder, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 10, 2025. Read the notice at the SEC.

equitySEC
Jun 2018$2 MNo. 5Under $2 million

CHD Bioscience, Inc.: Raise no. 5, Jun 2018

Investors in this round

19 investors had bought by the notice of Sep 25, 2018: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $10 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$490,062
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Colorado

People named in the notice

  • Dennis Templar · Executive Officer, Director
  • Robert Kali · Executive Officer
  • Ted Ziemann · Executive Officer, Director
  • Alan Ruud · Director
  • Alan Smith · Director
  • Ed Neas · Director
  • Michael Litwack · Director
  • Stephen Coder · Director
  • William Nelson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Arete Wealth Management, LLC (CRD 44856) · Chicago, IllinoisSold in all US states

Remarks in the notice

  • On fees: “Assumes maximum commissions earned by one or more non-exclusive agents or sub agents as more fully set forth in the offering materials. Excludes warrants to purchase 544,513 shares.”
  • On the use of proceeds: “Some of the proceeds may be used for general working capital purposes including the payment of salaries and other fees to those listed in Item 3.”

Signed by Robert Kali, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 25, 2018. Read the notice at the SEC.

equitySEC
Feb 2017$3 MNo. 4$2 to $10 million

CHD Bioscience, Inc.: Raise no. 4, Feb 2017

Investors in this round

7 investors had bought by the notice of Nov 17, 2017: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $14 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$840,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Colorado

People named in the notice

  • Dennis Templar · Executive Officer, Director
  • Ed Neas · Executive Officer, Director
  • Michael Handley · Executive Officer, Director
  • Robert Kali · Executive Officer
  • Ted Ziemann · Executive Officer, Director
  • Alan Ruud · Director
  • Alan Smith · Director
  • Michael Litwack · Director
  • Stephen Coder · Director
  • William Nelson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • TORREYA CAPITAL (CRD 16668) · New York, New YorkSold in all US states
  • CG CAPITAL MARKETS LLC (CRD 35513) · Boca Raton, FloridaSold in AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NY, OH, OK, OR, PA, PR, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY
  • PRECISION SECURITIES, LLC (CRD 103976) · San Diego, CaliforniaSold in AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, PR, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY

Remarks in the notice

  • On fees: “Assumes maximum commissions earned by one or more non-exclusive agents or sub agents as more fully set forth in the offering materials. Excludes warrants to purchase up to 1,272,727 shares.”
  • On the amounts: “This offering is closed.”
  • On the use of proceeds: “Some of the procedes may be used for general working capital purposes including the payment of salaries and other fees to those listed in Item 3.”

Signed by Robert Kali, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Nov 17, 2017. Read the notice at the SEC.

equity, optionsSEC
Jan 2016$3 MNo. 3$2 to $10 million

CHD Bioscience, Inc.: Raise no. 3, Jan 2016

Investors in this round

16 investors had bought by the notice of Jun 1, 2016: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $6 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$203,555
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Colorado

People named in the notice

  • Dennis Templar · Executive Officer, Director
  • Michael Handley · Executive Officer, Director
  • Robert Kali · Executive Officer
  • Ted Ziemann · Executive Officer, Director
  • Alan Ruud · Director
  • Alan Smith · Director
  • Ed Neas · Director
  • Loretta Mealy · Director
  • Michael Litwack · Director
  • Roy Carver, Jr. · Director
  • Stephen Coder · Director
  • William Nelson, V · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • BRISTOL INVESTMENT GROUP, INC. (CRD 39684) · broker-dealer DONENFELD, ALAN PAUL (CRD 1206842) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “Assumes maximum commission earned by placement agent. Commission only paid to investors first introduced by placement agent.”
  • On the use of proceeds: “Some of the procedes may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”

Signed by Robert Kali, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 1, 2016. Read the notice at the SEC.

equitySEC
Mar 2015$2 MNo. 2Under $2 million

CHD Bioscience, Inc.: Raise no. 2, Mar 2015

Investors in this round

19 investors had bought by the notice of Feb 26, 2016: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Colorado

People named in the notice

  • Dennis Templar · Executive Officer, Director
  • Michael Handley · Executive Officer, Director
  • Robert Kali · Executive Officer
  • Alan Smith · Director
  • Doug Coder · Director
  • Ed Neas · Director
  • Loretta Mealy · Director
  • Michael Litwack · Director
  • Roy, Jr. Carver · Director
  • Ted Ziemann · Director
  • William Nelson, V · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert Kali, VP Admin/CFO by Cynthia E. Moore, Attorney-in-Fact. Source: SEC Form D, newest notice filed Feb 26, 2016. Read the notice at the SEC.

equitySEC
Feb 2014$3 MNo. 1$2 to $10 million

CHD Bioscience, Inc.: Raise no. 1, Feb 2014

Investors in this round

20 investors had bought by the notice of Apr 17, 2014: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Colorado

People named in the notice

  • Dennis Templar · Executive Officer, Director
  • Michael Handley · Executive Officer
  • Robert Kali · Executive Officer
  • Alan Smith · Director
  • Cathy Sohn · Director
  • Doug Coder · Director
  • Ed Neas · Director
  • Loretta Mealy · Director
  • Michael Litwack · Director
  • Roy, Jr. Carver · Director
  • Ted Ziemann · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Rex O'Neal, Power of Attorney, Cfo. Source: SEC Form D and 1 amendment, newest notice filed Apr 17, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • CHD Bioscience, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2025).

    SEC Form D · Jul 2025

  • The industry group it chose in its notices: Other.

    SEC Form D · Jul 2025

That is all the official record says: CHD Bioscience, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of CHD Bioscience, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 20 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by CHD Bioscience, Inc.
NameRoleNamed in
Michael VossExecutive officerJul 2025
Steve CoderExecutive officerJul 2025
Dennis TemplarExecutive officerSep 2018
Robert KaliExecutive officerSep 2018
Ted ZiemannExecutive officerSep 2018
Ed NeasExecutive officerNov 2017
Michael HandleyExecutive officerNov 2017
Alan RuudDirectorJul 2025
Alan Smith, Ph.D.DirectorJul 2025
Christopher RuddDirectorJul 2025
Michael LitwackDirectorJul 2025
Michael VossDirectorJul 2025
Steve CoderDirectorJul 2025
Theodore ZiemannDirectorJul 2025
William Nelson, MD, Ph.D.DirectorJul 2025
Alan SmithDirectorSep 2018
Dennis TemplarDirectorSep 2018
Ed NeasDirectorSep 2018
Stephen CoderDirectorSep 2018
Ted ZiemannDirectorSep 2018
William NelsonDirectorSep 2018
Michael HandleyDirectorNov 2017
Loretta MealyDirectorJun 2016
Roy Carver, Jr.DirectorJun 2016
William Nelson, VDirectorJun 2016
Doug CoderDirectorFeb 2016
Roy, Jr. CarverDirectorFeb 2016
Cathy SohnDirectorApr 2014